ACE and diabetic kidney disease: Given that the majority of patients in FIDELIO-DKD were receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), this was the first study to show the validity of using the combination of two renin–angiotensin–aldosterone system (RAAS) inhibitors in reducing hard kidney and cardiovascular outcomes [9,63].